Xavier Rossello
Overview
Explore the profile of Xavier Rossello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
2999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Clin J Am Soc Nephrol
. 2024 Jul;
PMID: 38949880
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their use in patients with frailty and/or multimorbidity, among whom polypharmacy...
12.
Wussler D, Belkin M, Shrestha S, Wernicke H, Papachristou A, Nowak A, et al.
Eur J Heart Fail
. 2024 Jun;
26(8):1749-1758.
PMID: 38923253
Aims: We hypothesized that the current gold standard for risk stratification of patients with acute heart failure (AHF), the Multiple Estimation of risk based on the Emergency department Spanish Score...
13.
Cisneros-Barroso E, Rossello X
Eur J Heart Fail
. 2024 May;
26(7):1606-1607.
PMID: 38808622
No abstract available.
14.
Jentzer J, Rossello X
Eur Heart J Acute Cardiovasc Care
. 2024 May;
13(6):481-483.
PMID: 38757197
No abstract available.
15.
Gonzalez-Del-Hoyo M, Rossello X
Eur Heart J Acute Cardiovasc Care
. 2024 Apr;
13(5):446-448.
PMID: 38679618
No abstract available.
16.
Udell J, Petrie M, Jones W, Anker S, Harrington J, Mattheus M, et al.
J Am Coll Cardiol
. 2024 Apr;
83(23):2233-2246.
PMID: 38588929
Background: Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). Objectives: This study sought to evaluate...
17.
Butler J, Jones W, Udell J, Anker S, Petrie M, Harrington J, et al.
N Engl J Med
. 2024 Apr;
390(16):1455-1466.
PMID: 38587237
Background: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and...
18.
Hernandez A, Udell J, Jones W, Anker S, Petrie M, Harrington J, et al.
Circulation
. 2024 Apr;
149(21):1627-1638.
PMID: 38581389
Background: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction....
19.
Fernandez-Friera L, Garcia-Alvarez A, Oliva B, Garcia-Lunar I, Garcia I, Moreno-Arciniegas A, et al.
Eur Heart J Cardiovasc Imaging
. 2024 Mar;
25(7):968-975.
PMID: 38426763
Aims: Evidence on the association between subclinical atherosclerosis (SA) and cardiovascular (CV) events in low-risk populations is scant. To study the association between SA burden and an ischaemic scar (IS),...
20.